128 Chapter 5 Supplementary Table 2. Associations between PRS and APOE ε4 and biomarkers N OR PRS [CI] OR APOE [CI] Dichotomous biomarkers A- 549 reference reference A+ 106 1.5[1.2-1.9]* 3.5[2.4-5.1]* T- 451 reference reference T+ 193 1.1[0.9-1.3] 1.6[1.2-2.1]* N- 626 reference reference N+ 77 1.0[0.8-1.3] 1.4[1.0-2.0] ATN profiles A-T-N- 311 reference reference A-T-N+ 28 1.2[0.8-1.9] 1.2[0.6-2.5] A-T+N- 105 1.0[0.8-1.2] 1.5[1.0-2.3]* A-T+N+ 9 1.9[1.0-3.7] 1.9[0.7-5.4] A+T-N- 30 1.9[1.2-2.8]* 3.7[2.0-6.8]* A+T-N+ 10 0.7[0.3-1.4] 5.9[2.1-16.8]* A+T+N- 44 1.7[1.2-2.5]* 4.5[2.6-8.1]* A+T+N+ 6 1.3[0.6-3.1] 3.6[0.9-14.2] ATN categories Normal AD biomarkers 311 reference reference Non-AD pathologic change 142 1.1[0.9-1.4] 1.5[1.1-2.2]* Alzheimer’s continuum 90 1.5[1.1-2.1]* 4.2[2.6-6.7]* Values given are odds ratio (95% confidence interval) corrected for age, sex and population substructure, as estimated by logistic regression. The model included both APOE ε4 and normalized PRS as predictors. Outcome: dichotomous biomarker status for A, T and N separately (reference = negative biomarker status); eight-profile ATN classification (reference = A-T-N-); three-category ATN classification (reference = Normal AD biomarkers)). The odds ratio for the PRS reflects the odds of having an abnormal biomarker status or being classified in one of the ATN profiles with abnormal biomarkers, per one standard deviation increase in the PRS. APOE ε4 is per allele. * p-value <0.05. OR = odds ratio; PRS = polygenic risk score.
RkJQdWJsaXNoZXIy MjY0ODMw